Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors

AIDS

Volumn 16, Issue 1, 2002, Pages 113-119

  Machado, Daisy M ^a   Delwart, Eric L ^a   Diaz, Ricardo S ^a   De Oliveira, Carlos F ^a   Alves, Katia ^a   Rawal, Bhupat D ^a   Sullivan, Marian ^a   Gwinn, Marta ^a   Clark, Kenneth A ^a   Busch, Michael P ^a  

^a Blood Centers of the Pacific   (United States)

Author keywords

Acute infection; Detuned EIA; Epidemiology; HIV diagnostic tests; HIV sequence variability; Seroprevalence; Surveillance

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ACUTE DISEASE; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; DIAGNOSTIC TEST; ENZYME IMMUNOASSAY; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPTICAL DENSITY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROPREVALENCE; UNITED STATES; VIRAL GENETICS; VIRUS TYPING;

AIDS SERODIAGNOSIS; BLOOD DONORS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HETERODUPLEX ANALYSIS; HIV ANTIBODIES; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; MALE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

EID: 0037016476     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201040-00014     Document Type: Article

References (43)

1. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
2. Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco
3. Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989-1998: Application of the serologic testing algorithm for recent HIV seroconversion
4. HIV incidence among men who have sex with men-seven US cities, 1994-2000
5. Laboratory testing and rapid HIV assays: Applications for HIV surveillance in hard-to-reach populations
6. What a test for recent infection might reveal about HIV incidence in England and Wales
7. Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution
8. Genetic relationships determined by a heteroduplex mobility assay: Analysis of HIV env genes
9. Slower evolution of HIV-1 quasispecies during progression to AIDS
10. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission
11. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays
12. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection
13. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection
14. Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties
15. Gender differences in HIV-1 diversity at time of infection
16. Phenotype associated sequence variation in the third variable domain (V3) of the HIV-1 gp120 molecule
17. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: Phenotypic and genotypic characteristics. WHO network for HIV isolation and characterization
18. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: Syncytium-inducing variants seem rare among subtype C HIV-1 viruses
19. Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG
20. Genomic structure and nucleotide sequence analysis of a new HIV type 1 subtype A strain from Nigeria
21. Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence
22. Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution
23. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants
24. Spread of distinct human immunodeficiency virus type 1 AG recombinant lineages in Africa
25. Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay
26. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection
27. Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease
28. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection
29. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
30. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to Human Immunodeficiency Virus type 1 infection
31. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: A sentinel site for monitoring HIV genetic diversity in the United States
32. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1
33. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance
34. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs
35. Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors
36. Transmission of antiretroviral-drug-resistant HIV-1 variants
37. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
38. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group
39. Transmission and prevalence of HIV resistance among treatment-naive subjects
40. HIV-1 drug resistance in newly infected individuals
41. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel
42. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998
43. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study